Intracellular matrix metalloproteinase-2 (MMP-2) regulates human platelet activation via hydrolysis of talin

Area of Science:

• Hematology
• Molecular Biology
• Biochemistry

Background:

• Matrix metalloproteinases (MMPs) are enzymes typically associated with extracellular processes like tissue remodeling and tumor metastasis.
• Platelets contain MMPs (1, 2, and 9) that can influence agonist-induced platelet aggregation through extracellular signaling.
• Previous studies indicated that MMP inhibitors like 1,10-phenanthroline and serine protease inhibitors like AEBSF inhibit platelet aggregation.

Purpose of the Study:

• To investigate the intracellular role of MMP-2 in regulating agonist-induced platelet aggregation.
• To identify the specific molecular pathway involved in MMP-2-mediated platelet activation.
• To explore potential synergistic inhibition strategies for this newly identified pathway.

Main Methods:

• In vitro analysis of platelet aggregation inhibition using MMP inhibitors (1,10-phenanthroline) and serine protease inhibitors (AEBSF).
• Investigation of MMP-2's intracellular function in activating talin, a key factor for glycoprotein (GP)IIb/IIIa integrin activation.
• Co-immunoprecipitation and immunofluorescence studies to demonstrate the complex formation of intracellular MMP-2 with JAK 2 and STAT 3.
• Assessment of synergistic inhibition using 1,10-phenanthroline and a JAK 2 inhibitor.

Main Results:

• MMP-2 functions intracellularly to regulate platelet aggregation by activating talin, which leads to glycoprotein IIb/IIIa activation.
• Activated glycoprotein IIb/IIIa binds fibrinogen, a crucial step for platelet aggregation.
• Intracellular MMP-2 forms a complex with JAK 2 and STAT 3, confirmed by co-immunoprecipitation and immunofluorescence.
• A combination of a non-selective MMP inhibitor (1,10-phenanthroline) and a JAK 2 inhibitor synergistically inhibits the MMP-2 platelet activation pathway.
• This MMP-2 pathway is distinct from the previously described calpain-talin pathway.

Conclusions:

• A novel intracellular MMP-2 pathway regulates agonist-induced platelet aggregation via talin activation and subsequent glycoprotein IIb/IIIa signaling.
• The active intracellular MMP-2 is part of a complex with JAK 2 and STAT 3.
• This pathway offers new therapeutic targets for regulating platelet aggregation, distinct from existing mechanisms.
• Understanding this pathway enhances the comprehension of platelet activation complexity.